View Future GrowthPark Ha Biological Technology 過去の業績過去 基準チェック /06Park Ha Biological Technologyの収益は年間平均-83.5%の割合で減少していますが、 Specialty Retail業界の収益は年間 減少しています。収益は年間3.6% 10.4%割合で 増加しています。主要情報-83.53%収益成長率-82.10%EPS成長率Specialty Retail 業界の成長26.64%収益成長率10.36%株主資本利益率-609.90%ネット・マージン-965.00%前回の決算情報31 Oct 2025最近の業績更新Reported Earnings • Mar 04Full year 2025 earnings released: US$41.38 loss per share (vs US$0.96 profit in FY 2024)Full year 2025 results: US$41.38 loss per share (down from US$0.96 profit in FY 2024). Revenue: US$2.52m (up 6.0% from FY 2024). Net loss: US$24.4m (down US$24.8m from profit in FY 2024).Reported Earnings • Aug 27First half 2025 earnings released: US$0.74 loss per share (vs US$0.002 profit in 1H 2024)First half 2025 results: US$0.74 loss per share (down from US$0.002 profit in 1H 2024). Revenue: US$1.24m (up 45% from 1H 2024). Net loss: US$19.8m (down US$19.9m from profit in 1H 2024).Reported Earnings • Feb 25Full year 2024 earnings released: EPS: US$0.019 (vs US$0.034 in FY 2023)Full year 2024 results: EPS: US$0.019 (down from US$0.034 in FY 2023). Revenue: US$2.38m (down 3.1% from FY 2023). Net income: US$478.6k (down 44% from FY 2023). Profit margin: 20% (down from 35% in FY 2023). The decrease in margin was primarily driven by higher expenses.すべての更新を表示Recent updatesReported Earnings • Mar 04Full year 2025 earnings released: US$41.38 loss per share (vs US$0.96 profit in FY 2024)Full year 2025 results: US$41.38 loss per share (down from US$0.96 profit in FY 2024). Revenue: US$2.52m (up 6.0% from FY 2024). Net loss: US$24.4m (down US$24.8m from profit in FY 2024).New Risk • Feb 02New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 111% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 89% per year over the past 5 years. Shareholders have been substantially diluted in the past year (111% increase in shares outstanding). Market cap is less than US$10m (US$4.91m market cap). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (US$2.8m revenue).お知らせ • Jan 29Park Ha Biological Technology Co., Ltd. has completed a Composite Units Offering in the amount of $2.45 million.Park Ha Biological Technology Co., Ltd. has completed a Composite Units Offering in the amount of $2.45 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 21,875,000 Price\Range: $0.112 Discount Per Security: $0.008New Risk • Jan 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 89% per year over the past 5 years. Market cap is less than US$10m (US$4.95m market cap). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Revenue is less than US$5m (US$2.8m revenue).お知らせ • Sep 20Park Ha Biological Technology Co., Ltd. has filed a Follow-on Equity Offering.Park Ha Biological Technology Co., Ltd. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 11,428,571 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 11,428,571お知らせ • Sep 19Park Ha Biological Technology Co., Ltd., Annual General Meeting, Oct 03, 2025Park Ha Biological Technology Co., Ltd., Annual General Meeting, Oct 03, 2025, at 10:00 China Standard Time. Location: 901, building c phase 2, wuxi international life science innovation campus, 196 jinghui east road xinwu district, wuxi ChinaReported Earnings • Aug 27First half 2025 earnings released: US$0.74 loss per share (vs US$0.002 profit in 1H 2024)First half 2025 results: US$0.74 loss per share (down from US$0.002 profit in 1H 2024). Revenue: US$1.24m (up 45% from 1H 2024). Net loss: US$19.8m (down US$19.9m from profit in 1H 2024).分析記事 • Jul 10Some Park Ha Biological Technology Co., Ltd. (NASDAQ:PHH) Shareholders Look For Exit As Shares Take 94% PoundingPark Ha Biological Technology Co., Ltd. ( NASDAQ:PHH ) shareholders that were waiting for something to happen have been...New Risk • Jul 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$78.9m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Revenue has declined by 3.1% over the past year. Minor Risks Profit margins are more than 30% lower than last year (20% net profit margin). Revenue is less than US$5m (US$2.4m revenue). Market cap is less than US$100m (US$78.9m market cap).Reported Earnings • Feb 25Full year 2024 earnings released: EPS: US$0.019 (vs US$0.034 in FY 2023)Full year 2024 results: EPS: US$0.019 (down from US$0.034 in FY 2023). Revenue: US$2.38m (down 3.1% from FY 2023). Net income: US$478.6k (down 44% from FY 2023). Profit margin: 20% (down from 35% in FY 2023). The decrease in margin was primarily driven by higher expenses.New Risk • Jan 12New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid.お知らせ • Jan 08Park Ha Biological Technology Co., Ltd. Announces Appointment of Da Yang as an Independent DirectorOn January 7, 2025, the Board approved the appointment of Da Yang (Mr. Yang) as an independent director of the Park Ha Biological Technology Co., Ltd., effective January 7, 2025. Mr. Yang does not have a family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K. The biography for Mr. Yang is set forth below: Mr. Yang, aged 37, is an independent director of the Company. Mr. Yang has had many years of experience in sales and marketing. Mr. Yang served as the market director in Beijing New Space Technology Co., Ltd. since January 2021. From June 2017 to June 2020, Mr. Yang was a senior marketing manager in Gome Insurance Brokers Limited. From October 2015 to August 2016, Mr. Yang was an assistant to the general manager in Dade Liangju Trading (Beijing) Co., Ltd. Mr. Yang obtained his college degree in music performance (music) from Capital Normal University in 2008. The Board has determined that Mr. Yang qualifies as an independent director under the rules of the Nasdaq Stock Market LLC. In connection with his appointment, Mr. Yang will be entitled to receive the Company’s standard compensation provided to independent directors, pursuant to the independent director agreement between Mr. Yang and the Company.お知らせ • Dec 27Park Ha Biological Technology Co., Ltd. has completed an IPO in the amount of $4.8 million.Park Ha Biological Technology Co., Ltd. has completed an IPO in the amount of $4.8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,200,000 Price\Range: $4 Discount Per Security: $0.28収支内訳Park Ha Biological Technology の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqCM:BYAH 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Oct 253-2426031 Jul 253-2224030 Apr 253-1922031 Jan 253-911031 Oct 24201031 Jul 24201030 Apr 24201031 Jan 24211031 Oct 23211031 Oct 22201031 Oct 211010質の高い収益: BYAHは現在利益が出ていません。利益率の向上: BYAHは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: BYAHは利益が出ておらず、過去 5 年間で損失は年間83.5%の割合で増加しています。成長の加速: BYAHの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: BYAHは利益が出ていないため、過去 1 年間の収益成長をSpecialty Retail業界 ( -1.1% ) と比較することは困難です。株主資本利益率高いROE: BYAHは現在利益が出ていないため、自己資本利益率 ( -609.9% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YRetail 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 13:03終値2026/05/22 00:00収益2025/10/31年間収益2025/10/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Park Ha Biological Technology Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Mar 04Full year 2025 earnings released: US$41.38 loss per share (vs US$0.96 profit in FY 2024)Full year 2025 results: US$41.38 loss per share (down from US$0.96 profit in FY 2024). Revenue: US$2.52m (up 6.0% from FY 2024). Net loss: US$24.4m (down US$24.8m from profit in FY 2024).
Reported Earnings • Aug 27First half 2025 earnings released: US$0.74 loss per share (vs US$0.002 profit in 1H 2024)First half 2025 results: US$0.74 loss per share (down from US$0.002 profit in 1H 2024). Revenue: US$1.24m (up 45% from 1H 2024). Net loss: US$19.8m (down US$19.9m from profit in 1H 2024).
Reported Earnings • Feb 25Full year 2024 earnings released: EPS: US$0.019 (vs US$0.034 in FY 2023)Full year 2024 results: EPS: US$0.019 (down from US$0.034 in FY 2023). Revenue: US$2.38m (down 3.1% from FY 2023). Net income: US$478.6k (down 44% from FY 2023). Profit margin: 20% (down from 35% in FY 2023). The decrease in margin was primarily driven by higher expenses.
Reported Earnings • Mar 04Full year 2025 earnings released: US$41.38 loss per share (vs US$0.96 profit in FY 2024)Full year 2025 results: US$41.38 loss per share (down from US$0.96 profit in FY 2024). Revenue: US$2.52m (up 6.0% from FY 2024). Net loss: US$24.4m (down US$24.8m from profit in FY 2024).
New Risk • Feb 02New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 111% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 89% per year over the past 5 years. Shareholders have been substantially diluted in the past year (111% increase in shares outstanding). Market cap is less than US$10m (US$4.91m market cap). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (US$2.8m revenue).
お知らせ • Jan 29Park Ha Biological Technology Co., Ltd. has completed a Composite Units Offering in the amount of $2.45 million.Park Ha Biological Technology Co., Ltd. has completed a Composite Units Offering in the amount of $2.45 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 21,875,000 Price\Range: $0.112 Discount Per Security: $0.008
New Risk • Jan 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 89% per year over the past 5 years. Market cap is less than US$10m (US$4.95m market cap). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Revenue is less than US$5m (US$2.8m revenue).
お知らせ • Sep 20Park Ha Biological Technology Co., Ltd. has filed a Follow-on Equity Offering.Park Ha Biological Technology Co., Ltd. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 11,428,571 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 11,428,571
お知らせ • Sep 19Park Ha Biological Technology Co., Ltd., Annual General Meeting, Oct 03, 2025Park Ha Biological Technology Co., Ltd., Annual General Meeting, Oct 03, 2025, at 10:00 China Standard Time. Location: 901, building c phase 2, wuxi international life science innovation campus, 196 jinghui east road xinwu district, wuxi China
Reported Earnings • Aug 27First half 2025 earnings released: US$0.74 loss per share (vs US$0.002 profit in 1H 2024)First half 2025 results: US$0.74 loss per share (down from US$0.002 profit in 1H 2024). Revenue: US$1.24m (up 45% from 1H 2024). Net loss: US$19.8m (down US$19.9m from profit in 1H 2024).
分析記事 • Jul 10Some Park Ha Biological Technology Co., Ltd. (NASDAQ:PHH) Shareholders Look For Exit As Shares Take 94% PoundingPark Ha Biological Technology Co., Ltd. ( NASDAQ:PHH ) shareholders that were waiting for something to happen have been...
New Risk • Jul 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$78.9m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Revenue has declined by 3.1% over the past year. Minor Risks Profit margins are more than 30% lower than last year (20% net profit margin). Revenue is less than US$5m (US$2.4m revenue). Market cap is less than US$100m (US$78.9m market cap).
Reported Earnings • Feb 25Full year 2024 earnings released: EPS: US$0.019 (vs US$0.034 in FY 2023)Full year 2024 results: EPS: US$0.019 (down from US$0.034 in FY 2023). Revenue: US$2.38m (down 3.1% from FY 2023). Net income: US$478.6k (down 44% from FY 2023). Profit margin: 20% (down from 35% in FY 2023). The decrease in margin was primarily driven by higher expenses.
New Risk • Jan 12New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid.
お知らせ • Jan 08Park Ha Biological Technology Co., Ltd. Announces Appointment of Da Yang as an Independent DirectorOn January 7, 2025, the Board approved the appointment of Da Yang (Mr. Yang) as an independent director of the Park Ha Biological Technology Co., Ltd., effective January 7, 2025. Mr. Yang does not have a family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K. The biography for Mr. Yang is set forth below: Mr. Yang, aged 37, is an independent director of the Company. Mr. Yang has had many years of experience in sales and marketing. Mr. Yang served as the market director in Beijing New Space Technology Co., Ltd. since January 2021. From June 2017 to June 2020, Mr. Yang was a senior marketing manager in Gome Insurance Brokers Limited. From October 2015 to August 2016, Mr. Yang was an assistant to the general manager in Dade Liangju Trading (Beijing) Co., Ltd. Mr. Yang obtained his college degree in music performance (music) from Capital Normal University in 2008. The Board has determined that Mr. Yang qualifies as an independent director under the rules of the Nasdaq Stock Market LLC. In connection with his appointment, Mr. Yang will be entitled to receive the Company’s standard compensation provided to independent directors, pursuant to the independent director agreement between Mr. Yang and the Company.
お知らせ • Dec 27Park Ha Biological Technology Co., Ltd. has completed an IPO in the amount of $4.8 million.Park Ha Biological Technology Co., Ltd. has completed an IPO in the amount of $4.8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,200,000 Price\Range: $4 Discount Per Security: $0.28